Protagonist Therapeutics reported second quarter 2026 financial results, posting net income of $162.8 million ($2.47 basic EPS) compared to a net loss of $34.8 million in the prior year period. The company holds $849.5 million in cash and marketable securities as of June 30, 2026. Revenue surged to $213.5 million, driven by $192.4 million from proportional recognition of Takeda's $200 million rusfertide opt-out payment and $21.1 million for development services. Rusfertide remains under FDA priority review with a PDUFA date in August 2026. ICOTYDE, licensed to Johnson & Johnson, marked its first full quarter of commercial sales following March 2026 approval. The company announced plans to initiate a comprehensive Phase 2b program for PN-881 in early Q1 2027 and has begun Phase 1 studies for the obesity candidate PN-477sc. Protagonist Therapeutics is a biopharmaceutical company focused on discovering and developing peptide therapeutics.

On June 17, 2026, Protagonist Therapeutics, Inc. held its Annual Meeting of Stockholders, where shareholders approved the adoption of the 2026 Equity Incentive Plan. This new plan replaces the 2016 Equity Incentive Plan and authorizes the issuance of 650,000 new shares plus any remaining shares from the 2016 plan and forfeited or expired awards. Stockholders also elected Class I directors Dinesh V. Patel and Lewis T. Williams, ratified Ernst & Young LLP as the independent auditor, and approved executive compensation on an advisory basis. The company is a biopharmaceutical company that develops therapies for inflammatory and autoimmune diseases.